ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer

Published:2015-04-03 Issue:5 Volume:97 Page:447-450
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Gerber DE¹,Oxnard GR²,Govindan R³

Affiliation:

1. Division of Hematology and Oncology, Harold C. Simmons Cancer Center; UT Southwestern Medical Center; Dallas Texas USA

2. Department of Medicine; Harvard Medical School, Dana-Farber Cancer Institute; Boston Massachusetts USA

3. Division of Oncology, Department of Medicine; Washington University School of Medicine; St. Louis Missouri USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.91/fullpdf

Reference5 articles.

1. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci. Transl. Med.,2011

2. Management and future directions in non-small cell lung cancer with known activating mutations;Gerber;Am. Soc. Clin. Oncol. Educ. Book,2014

3. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J. Clin. Oncol.,2008

4. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project;Blackhall;J. Clin. Oncol,2014

5. Worse disease-free survival in never-smokers with ALK + lung adenocarcinoma;Yang;J. Thorac. Oncol.,2012

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts?;Interdisciplinary Cancer Research;2023

2. Design and analysis of umbrella trials: Where do we stand?;Frontiers in Medicine;2022-10-12

3. Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer;Biomedicines;2022-06-28

4. Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential;BMC Rheumatology;2021-07-02

5. Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods;Pharmaceutical Statistics;2021-03-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3